Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and

Lucas R Massoth1, Yin P Hung1, Valentina Nardi1

  • 1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Insights

KMT2A gene fusions drive rare sarcomas, often affecting young adults. YAP1 is the most common fusion partner, leading to complex rearrangements and sclerosing epithelioid fibrosarcoma-like tumors.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Sarcomas are a heterogeneous group of cancers with diverse genetic drivers.
  • Gene rearrangements, particularly KMT2A fusions, are implicated in a subset of sarcomas.
  • Limited clinicopathologic and molecular data exist for KMT2A-rearranged sarcomas.

Purpose of the Study:

  • To identify and characterize KMT2A fusion-positive sarcomas.
  • To elucidate the clinicopathologic and molecular features of these rare tumors.
  • To determine common rearrangement partners and concurrent genetic alterations.

Main Methods:

  • Targeted next-generation RNA sequencing for initial identification.
  • Systematic search for KMT2A structural variants in a large sarcoma database (14,680 cases).
  • Comprehensive clinicopathologic and molecular profiling of identified cases.

Main Results:

  • Identified 34 sarcomas (0.2%) with KMT2A fusions.
  • YAP1 was the predominant fusion partner (47%), often forming complex YAP1-KMT2A-YAP1 rearrangements.
  • Tumors predominantly affected younger adults and showed sclerosing epithelioid fibrosarcoma-like morphology.
  • Two VIM-KMT2A fusion sarcomas had distinct mutations and histology.
  • Other KMT2A-rearranged sarcomas showed diverse histologic subtypes and novel fusion partners.

Conclusions:

  • KMT2A-fusion-positive sarcomas are rare but distinct entities.
  • Complex YAP1-KMT2A-YAP1 fusions are characteristic of the most common subtype.
  • These findings expand the understanding of sarcoma pathogenesis and classification.